North East and North Cumbria
ICS Formulary
ICS Formulary
2 Cardiovascular system
02-05-05-01 Angiotensin-converting enzyme inhibitors (ACE inhibitors)
| Enalapril |
|
Formulary
|
|
|
| Enalapril orodispersible tablets Aqumeldi® |
|
Formulary
|
|
|
| Perindopril erbumine |
|
Formulary
|
|
 Items not to be routinely prescribed in primary care |
|
|
| Captopril |
|
Formulary
|
|
|
|
unlicensed.Links
- Academic Health Science Network (North East and North Cumbria) - Atrial Fibrilation
- Items not to be routinely prescribed in primary care
- MHRA Drug Safety Update (Dec 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016
- MHRA Drug Safety Update (Feb 2016): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia.
- MHRA Drug Safety Update (June 2014): Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function—new warnings
- NICE ES24: COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19
- NICE NG148: Acute kidney injury: prevention, detection and management
- NICE NG185: Acute coronary syndromes
- NICE NG191: COVID-19 rapid guideline: managing COVID-19